- Home
- DMAC vs BIOA Comparison
DMAC vs BIOA Comparison
Compare DMAC & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- BIOA
- Stock Information
- Founded
- DMAC 2000
- BIOA 2015
- Country
- DMAC United States
- BIOA United States
- Employees
- DMAC N/A
- BIOA N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- BIOA Biotechnology: Pharmaceutical Preparations
- Sector
- DMAC Health Care
- BIOA Health Care
- Exchange
- DMAC Nasdaq
- BIOA Nasdaq
- Market Cap
- DMAC 178.0M
- BIOA 153.4M
- IPO Year
- DMAC N/A
- BIOA 2024
- Fundamental
- Price
- DMAC $3.76
- BIOA $4.28
- Analyst Decision
- DMAC Strong Buy
- BIOA Hold
- Analyst Count
- DMAC 2
- BIOA 4
- Target Price
- DMAC $8.00
- BIOA $5.67
- AVG Volume (30 Days)
- DMAC 307.4K
- BIOA 338.3K
- Earning Date
- DMAC 08-06-2025
- BIOA 08-15-2025
- Dividend Yield
- DMAC N/A
- BIOA N/A
- EPS Growth
- DMAC N/A
- BIOA N/A
- EPS
- DMAC N/A
- BIOA N/A
- Revenue
- DMAC N/A
- BIOA $1,451,000.00
- Revenue This Year
- DMAC N/A
- BIOA N/A
- Revenue Next Year
- DMAC N/A
- BIOA N/A
- P/E Ratio
- DMAC N/A
- BIOA N/A
- Revenue Growth
- DMAC N/A
- BIOA N/A
- 52 Week Low
- DMAC $2.80
- BIOA $2.88
- 52 Week High
- DMAC $6.82
- BIOA $26.62
- Technical
- Relative Strength Index (RSI)
- DMAC 47.18
- BIOA N/A
- Support Level
- DMAC $3.48
- BIOA N/A
- Resistance Level
- DMAC $3.99
- BIOA N/A
- Average True Range (ATR)
- DMAC 0.32
- BIOA 0.00
- MACD
- DMAC -0.00
- BIOA 0.00
- Stochastic Oscillator
- DMAC 41.01
- BIOA 0.00
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About BIOA BioAge Labs Inc. Common Stock
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.